(Onvatilimab)Biosimilar Reference Antibody-GS40507 新品

货号：GS40507

Onvatilimab (also known as JNJ‑61610588 or CI‑8993) is a humanized IgG1‑kappa monoclonal antibody that targets V‑domain Ig suppressor of T‑cell activation (VISTA), an inhibitory immune checkpoint protein. As an IgG1 isotype, it is designed to potentially engage immune effector functions such as antibody‑dependent cellular cytotoxicity (ADCC). By binding to VISTA, onvatilimab blocks its interaction with ligands (e.g., VSIG3, PSGL‑1), thereby reversing VISTA‑mediated suppression of T‑cell activation and cytokine production. It is being developed as an immune checkpoint inhibitor for the treatment of advanced solid tumors, with the aim of restoring anti‑tumor immunity, particularly in combination with other immunotherapies.